Research programme: therapeutic cancer vaccines - NCI/Intensity Therapeutics

Drug Profile

Research programme: therapeutic cancer vaccines - NCI/Intensity Therapeutics

Alternative Names: INT 223-8

Latest Information Update: 09 Mar 2017

Price : $50

At a glance

  • Originator Intensity Therapeutics
  • Developer Intensity Therapeutics; National Cancer Institute (USA)
  • Class Cancer vaccines; Platinum complexes
  • Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors; Immunostimulants; Natural killer cell receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 02 Jun 2014 Therapeutic cancer vaccines are available for licensing as of 02 Jun 2014. http://www.intensitytherapeutics.com/index.html
  • 28 May 2014 Intensity Therapeutics establishes CRADA with National Cancer Institute for the development of therapeutic cancer vaccines
  • 28 May 2014 Preclinical trials in Cancer in USA (Intratumoural)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top